Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)

• Type: Article in International Scientific Journal
• Date: 2016

Authors

Montorsi, F (Author) Other; Gandaglia, G (Author) Other; Chapple, C (Author) Other; Francisco Cruz (Author) FMUP; Desgrandchamps, F (Author) Other; Llorente, C (Author) Other

Journal

Title: International Journal of Urology

Vol. 23

Pages: 572-579

ISSN: 0919-8172

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 10 Citations

Scopus - 16 Citations

Other information

Authenticus ID: P-00K-MJ6

DOI: 10.1111/iju.13088

Abstract (EN): Objectives: To assess the benefit-risk balance of silodosin in a real-life setting of benign prostatic hyperplasia patients with lower urinary tract symptoms. Methods: A phase IV trial including men aged >= 60 years with a clinical diagnosis of benign prostatic hyperplasia with an International Prostate Symptom Score >= 12 was carried out. Patients received silodosin 8 mg for 24 weeks. The primary end-point was a decrease >= 25% in the total International Prostate Symptom Score. Secondary end-points were: changes in total, storage and voiding, and quality of life International Prostate Symptom Scores; changes in the International Continence Society-male questionnaire; changes in the frequency/volume chart; and satisfaction according to the Patient Perception of Study Medication questionnaire. Treatment-emergent adverse events were recorded. Results: Overall, 1036 patients were enrolled. Of these, 766 patients (77.1%) had a decrease >= 25% in the total International Prostate Symptom Score. The mean total International Prostate Symptom Score, and storage and voiding symptoms subscores decreased from 18.9, 8.1 and 10.8 to 10.6, 4.9 and 5.7. Nocturia decreased from 85.7% to 52.4%. The mean International Prostate Symptom Score quality of life score decreased from 4.0 to 2.2. Half of the patients reported an improvement in the frequency and bothersomeness of the most frequent symptoms reported at baseline (all P < 0.001). A reduction in the number of voids was documented by the frequency/volume chart data. The most common treatment-emergent adverse event was ejaculation failure (185 patients; 17.9%), which led to study discontinuation in 2.4% of patients. Overall, 74.2% of patients were satisfied with the medication. Conclusions: Silodosin improved lower urinary tract symptoms in three out of four patients, including diurnal voiding and storage symptoms, nocturia, and quality of life. This treatment showed a favorable safety profile in this setting.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8